-
Russia jails veteran who threatened Putin with mutiny
-
Three things we learned from the Austrian F1 Grand Prix
-
Five shot dead at German youth welfare site, two suspects arrested
-
Burnham pledges radical devolution of UK govt if PM
-
New Zealand thrash England to deny Stokes a fairytale finish
-
Polish businesses press Warsaw, Kyiv to end political rift
-
Tour de France 'ready to adapt' amid extreme heatwave
-
Hovland beats Scheffler in playoff for PGA Travelers title
-
Stocks rise, oil climbs after US-Iran clashes
-
New Zealand thrash England for series win as Stokes bows out
-
Man City hire Maresca to start new era after Guardiola
-
Trump says Iran meeting to take place in Qatar
-
Pegula slams Vondrousova's 'harsh' doping ban
-
Spain raises 2026 growth forecast despite Mideast war turmoil
-
Chavez-era housing complex in ruins after Venezuela quakes
-
Kenya-US rare earths deal challenged in court over secrecy
-
Sinner, Djokovic set to start Wimbledon title charge
-
Santner strikes as New Zealand eye England series win
-
Pakistan launches deadliest attack on Afghanistan in months
-
Broos may change decision to quit as South Africa coach
-
Strauss 'dumbfounded' by timing of Stokes's England exit
-
French swim star Marchand suffers injury scare before Europeans
-
Monza turn to Juric for return to Serie A
-
France skipper Dupont to miss Nations Championship
-
Stocks mixed, oil edges up after US-Iran clashes
-
Springbok milestones loom for Willemse and Kolbe against England
-
Catholic traditionalists risk schism in Church
-
Tennis players end Wimbledon prize-money protest
-
Europe's deadly heatwave scorches eastern flank, takes aim at Ukraine
-
Pogacar rides with Del Toro and Yates in quest for fifth Tour de France
-
PSG in talks with Leipzig to buy Ivory Coast star Diomande
-
Australia to host Brazil double-header after World Cup
-
Venezuela search teams scramble as hope fades of finding quake survivors
-
Stocks rise and oil edges up as US, Iran call end to latest attacks
-
Bondi Beach attack survivor tells of 'trauma' of online AI images
-
South Korea to invest nearly $1.2 tn in chips, AI data centres
-
Pakistan strikes on eastern Afghanistan kill dozens
-
Russia rallies support for army with 'patriotic' tourist routes
-
Cape Verde, Africa's outlier in LGBTQ tolerance
-
Brazil, Germany eye World Cup last 16 as Netherlands face Morocco
-
South Korea demands change after dismal World Cup exit
-
Washington says US, Iran pausing strikes, talks to proceed
-
Stocks mixed and oil rises as US, Iran call end to latest attacks
-
EU, China trade tensions loom over minister visit
-
For sale on Facebook: monkeys, rhino horn and dead pangolins
-
Israelis, Palestinians torn over sacred shrine in city of Hebron
-
In Sudan's Kordofan, a key city reels as paramilitary offensive looms
-
Scheffler to face Hovland in Monday playoff for PGA Travelers title
-
Ryu Hae-ran wins Women's PGA Championship
-
'Burnt out' Stokes leaves England facing tricky questions
Ketamine pill treats depression without psychedelic effects: study
A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.
First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".
However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.
In many countries, ketamine has been prescribed for depression for years.
US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".
The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.
Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.
There are also fears that medical use of the drug could slide into abuse.
The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.
"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.
"I don't think these tablets would appeal to people who are abusing ketamine."
- Electro-shock alternative -
The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.
More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.
Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.
Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.
Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.
"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.
This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.
But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".
- Fears of 'opioid style crisis' -
Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.
Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.
US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.
One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.
But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.
By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.
There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.
More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.
H.Thompson--AT